A practical guide about biosimilar data for health care providers treating inflammatory diseases

por Markenson, Joseph, Alvarez, Daniel F, Jacobs, Ira, Kirchhoff, Carol
Publicado 2017

Drug tendering: drug supply and shortage implications for the uptake of biosimilars

por Dranitsaris, George, Jacobs, Ira, Kirchhoff, Carol, Popovian, Robert, Shane, Lesley G
Publicado 2017

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

por Jacobs, Ira, Petersel, Danielle, Shane, Lesley G., Ng, Chee-Keng, Kirchhoff, Carol, Finch, Gregory, Lula, Sadiq
Publicado 2016

Biosimilars: Key regulatory considerations and similarity assessment tools

por Kirchhoff, Carol F., Wang, Xiao‐Zhuo Michelle, Conlon, Hugh D., Anderson, Scott, Ryan, Anne M., Bose, Arindam
Publicado 2017

The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product...

por McClellan, Joseph E., Conlon, Hugh D., Bolt, Michael W., Kalfayan, Vatche, Palaparthy, Rameshraja, Rehman, Muhammad I., Kirchhoff, Carol F.
Publicado 2019

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)

por Derzi, Mazin, Johnson, Theodore R., Shoieb, Ahmed M., Conlon, Hugh D., Sharpe, Penny, Saati, Andrew, Koob, Sarah, Bolt, Michael W., Lorello, Leslie G., McNally, Jim, Kirchhoff, Carol F., Smolarek, Teresa A., Leach, Michael W.
Publicado 2016